Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has shared an update.
Shanghai Pharmaceuticals Holding Co., Ltd. held its second extraordinary general meeting of 2025, where key resolutions were passed, including the abolishment of the Supervisory Board and amendments to the Articles of Association. The meeting, which adhered to the legal requirements of the People’s Republic of China, saw significant shareholder participation, with a high percentage of votes in favor of the proposed changes, indicating strong support for the company’s strategic direction.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a leading company in the pharmaceutical industry in China, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company operates primarily in the Chinese market, providing a wide range of healthcare products and services.
Average Trading Volume: 3,061,652
Technical Sentiment Signal: Buy
Current Market Cap: HK$66.15B
For an in-depth examination of 2607 stock, go to TipRanks’ Overview page.